10Y annualized return is
positive but below market average
at 1.4% per year
MO has met or exceeded earnings expectations in
some
recent quarters (6/10)
Low PE Ratio Indicates Value
Strong Free Cash Flow Yield
Strong Profit Margins
Strong Interest Coverage
💰 Strong Financial Performance
🚀 Innovation in Smoke-Free Products
📈 Competitive Position in Premium Segment
🌱 Growth in Smoke-Free Alternatives
🔍 Regulatory Opportunities
📊 Strategic Investment Plans
High Price to Sales Ratio
Negative Price to Book Ratio
Negative Return on Equity
High Debt Levels
Weak Liquidity Ratios
📉 Declining Cigarette Volumes
⚠️ Illicit Market Challenges
🔄 Reassessment of Goals
💡 Patent Challenges
Overall, Altria demonstrates a solid business model with a strong focus on innovation within smoke-free products. However, challenges such as declining cigarette volumes and the illicit market threaten its growth potential. The company remains committed to strategic investments and navigating the regulatory landscape to enhance future opportunities.
Analysis Date: January 30, 2025
Last Updated: March 12, 2025
Past performance does not guarantee future results. The data presented is indicative and may not be updated in real-time.
Altria Group, Inc. is a company that makes and sells tobacco products in the United States. They are best known for their cigarettes, especially the Marlboro brand, but they also sell cigars, pipe tobacco, and smokeless tobacco products like Copenhagen and Skoal. Altria sells these products mainly to wholesalers and large stores. Founded in 1822, the company is based in Richmond, Virginia.
Streams of revenue
Geographic Distribution
Core Products
Business Type
Business to Consumer
Competitive Advantages
Key Business Risks
Latest News
Shares of Altria Group Inc. ( NYSE: MO ) have outperformed the broad market over the past month by mustering a gain of 1.60% while the S&P 500 has los...
Altria (MO) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the ...
Investors should remain calm amid market volatility and consider buying during price dips, with 2025 expected to see more turbulence. Kenvue's strong ...
Trailing Twelve Months (TTM) values provide a view of the company's performance over the last year.
Benjamin Graham's value investing approach focuses on finding stocks with a significant margin of safety between their intrinsic value and market price.
Intrinsic Value
Estimated fair value based on Graham's formula
$255.43
Current Market Price: $55.84
IV/P Ratio: 4.57x (>1.0 indicates undervalued)
Margin of Safety
Gap between intrinsic value and market price
78.0%
Graham recommended a minimum of 20-30% margin of safety
Higher values indicate a greater potential discount to fair value
Graham Criteria Checklist
Benjamin Graham's value investing checklist for MO
Positive earnings (5+ years)
Dividend history (5+ years)
P/E ratio ≤ 20 (8.45)
P/B ratio ≤ 1.5 (-42.54)
Current ratio ≥ 2.0 (0.51x)
Long-term debt < Net current assets (-5.48x)
Margin of safety (78.0%)
MO does not meet all Graham criteria
Trailing Twelve Months (TTM) values provide a view of the company's performance over the last year.
Profitability metrics measure a company's ability to generate earnings relative to its revenue, operating costs, and other relevant metrics. Higher values generally indicate better performance.
Return on Equity (ROE)
Measures how efficiently a company uses its equity to generate profits
-333.94%
Higher values indicate better returns for shareholders
TTM (as of 2025-04-30)
Gross Profit Margin
Percentage of revenue retained after accounting for cost of goods sold
70.27%
Higher values indicate better efficiency in production
TTM (as of 2025-04-30)
Net Profit Margin
Percentage of revenue retained after accounting for all expenses
55.10%
Higher values indicate better overall profitability
TTM (as of 2025-04-30)
The company has high gross profit margin (70.27%) and net profit margin (55.10%), indicating efficient cost management and strong profitability.
The return on equity (ROE) of -3.26% is concerning, indicating that the company is not effectively using shareholders' equity to generate profits.
Financial health metrics assess a company's ability to meet its financial obligations and its overall financial stability.
Debt to Equity Ratio
Total debt divided by total equity
-11.39x
Lower values indicate less financial leverage and risk
Less than 1.0 is conservative, 1.0-2.0 is moderate, >2.0 indicates high risk
Q4 2024
Current Ratio
Current assets divided by current liabilities
0.51x
Higher values indicate better short-term liquidity
Less than 1.0 is concerning, 1.0-2.0 is adequate, greater than 2.0 is good
Q4 2024
An interest coverage ratio of 10.38 suggests that the company can comfortably meet its interest obligations, indicating solid financial health.
A debt-to-equity ratio of -11.14 and a debt-to-assets ratio of 70.86% indicate significant leverage, which may pose risks in a downturn.
Current (0.51) and quick ratios (0.39) below 1.0 indicate potential liquidity issues, suggesting that the company may struggle to cover short-term obligations.
Meeting Expectations
Higher values indicate better execution and credibility
Recent Results
EPS
Revenue
Altria demonstrated solid financial results with a 3.4% growth in adjusted diluted earnings per share and over $10.2 billion returned to shareholders through dividends and share repurchases.
Altria is actively investing in smoke-free alternatives, with NJOY's significant growth in market share and volume, as well as the introduction of innovative products like on! and Ploom.
Marlboro continues to hold a strong position in the premium cigarette segment, maintaining a retail share of 59.4%, indicating strong brand equity.
Domestic cigarette volumes declined by 10.2% for the year, reflecting ongoing challenges in the smokable product segment and shifts towards smoke-free alternatives.
The growth of illicit disposable e-vapor products poses a significant threat to Altria's market share and the overall regulatory environment, complicating their strategy for smoke-free products.
The increasing adoption of smoke-free products presents a significant opportunity for Altria, with the potential to shift millions of smokers to FDA-authorized alternatives.
The potential for improved regulatory oversight and enforcement against illicit products could enhance the market for legitimate smoke-free products, benefiting Altria's growth.
Altria plans to invest in market activities for smoke-free products and continue research and development, indicating a commitment to long-term growth.
Altria is reassessing its 2028 enterprise goals due to the unexpected growth of the illicit e-vapor market, which may hinder future growth targets.
Ongoing litigation and patent challenges, particularly regarding NJOY, could impact the company's ability to capitalize on the e-vapor market effectively.
Insider trading data shows purchase and sale activities by company executives and board members.
Insider trading patterns can provide insights into how company executives and board members view the stock's future prospects.
Insiders are buying significantly more than selling (ratio: 2.09x)
Total Bought
Total value of insider purchases in recent quarters
$326288
Higher values indicate stronger insider confidence
Total Sold
Total value of insider sales in recent quarters
$156029
Lower values relative to buying indicate possible undervaluation
Active Insiders
Number of insiders trading in recent quarters
1
Limited insider activity
Recent Trend
Change in insider trading pattern
MO: No trend data available